2-Sep-2026
Small-cap bears were back. Was IWM the warning sign?
Seeking Alpha News (Wed, 2-Sep 11:29 AM ET)
Ten healthcare stocks leading in year-over-year CapEx growth
Seeking Alpha News (Wed, 2-Sep 8:02 AM ET)
Top Glaukos Executive Makes Bold Insider Move in High-Value Stock Sale
TipRanks (Tue, 1-Sep 10:06 PM ET)
Glaukos Announces Participation in Wells Fargo Healthcare Conference
Business Wire (Wed, 19-Aug 7:00 AM ET)
Glaukos Announces Second Quarter 2026 Financial Results
Business Wire (Wed, 29-Jul 4:05 PM ET)
Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO MicroShunt
Business Wire (Mon, 27-Jul 7:00 AM ET)
Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29
Business Wire (Wed, 8-Jul 7:00 AM ET)
Business Wire (Thu, 25-Jun 7:00 AM ET)
Glaukos Delivers Record Q1 2026 Sales and Raises Full-Year Guidance on Glaucoma Division Strength
Market Chameleon (Thu, 30-Apr 7:54 AM ET)
Market Chameleon (Thu, 19-Mar 5:06 AM ET)
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Glaukos trades on the NYSE stock market under the symbol GKOS.
As of September 2, 2026, GKOS stock price climbed to $179.53 with 695,653 million shares trading.
GKOS has a beta of 0.31, meaning it tends to be less sensitive to market movements. GKOS has a correlation of 0.00 to the broad based SPY ETF.
GKOS has a market cap of $10.59 billion. This is considered a Large Cap stock.
Last quarter Glaukos reported $186 million in Revenue and -$.14 earnings per share. This beat revenue expectation by $35 million and exceeded earnings estimates by $.09.
In the last 3 years, GKOS traded as high as $191.62 and as low as $59.22.
The top ETF exchange traded funds that GKOS belongs to (by Net Assets): IJR, VTI, IWM, VB, VBK.
GKOS has outperformed the market in the last year with a return of +91.1%, while the SPY ETF gained +20.7%. In the last 3 month period, GKOS beat the market returning +62.1%, while SPY returned +1.0%. However, in the most recent 2 weeks GKOS has underperformed the stock market by returning -5.3%, while SPY returned -0.5%.
GKOS support price is $172.65 and resistance is $180.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GKOS shares will trade within this expected range on the day.